Tag: Sorrento Therapeutics


Sorrento Therapeutics Inc (NASDAQ: SRNE) Gets EUA Endorsement and Import License From Mexico Authority COFEPRIS for COVI-STIX™

Sorrento Therapeutics Inc (NASDAQ: SRNE) has announced that it has received Gets EUA Endorsement and Import License from Mexico Authority COFEPRIS for COVI-STIX™. COVI-STIX is a subtle and quick investigative examination for the uncovering of the SARS-CoV-2 disease. COFEPRIS delivered an Emergency Use Authorization (EUA) authorization and an import license […]


Sorrento Therapeutics Inc (NASDAQ: SRNE) And Mayo Clinic Move Into A Research Collaboration Agreement

The stock of Sorrento Therapeutics Inc (NASDAQ: SRNE) rose to $9.46 after gaining 6.65%. The company moves into a research collaboration agreement that will rely upon the Sofusa Lymphatic Drug Delivery System (S-LDDS) technology in its undertakings. It collaborates with Mayo Clinic in the deal, hoping to make a breakthrough in the […]


Sorrento Therapeutics Inc. (NASDAQ: SRNE) Gains After MHRA Clears COVI-DROPS For Phase 2 Study

Sorrento Therapeutics Inc. (NASDAQ: SRNE) gained 1.6% after announcing the UK’s regulatory agency Medicines and Healthcare products Regulatory Agency cleared its COVI-DROPS candidate for a second phase efficacy study. MHRA clears Sorrento’s COVI-DROPS Application The company submitted the application as a rolling application with the MHRA clearing the trial within […]